These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29745790)

  • 21. Germline mutations of the E-cadherin gene (CDH1) in early onset gastric cancer.
    Corso G; Roviello F
    Semin Oncol; 2020; 47(2-3):125-126. PubMed ID: 32416945
    [No Abstract]   [Full Text] [Related]  

  • 22. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast.
    Chan JK; Wong CS
    Adv Anat Pathol; 2001 May; 8(3):165-72. PubMed ID: 11345240
    [No Abstract]   [Full Text] [Related]  

  • 23. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred.
    Oliveira C; Bordin MC; Grehan N; Huntsman D; Suriano G; Machado JC; Kiviluoto T; Aaltonen L; Jackson CE; Seruca R; Caldas C
    Hum Mutat; 2002 May; 19(5):510-7. PubMed ID: 11968083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome.
    Molinaro V; Pensotti V; Marabelli M; Feroce I; Barile M; Pozzi S; Laghi L; Serrano D; Bernard L; Bonanni B; Ranzani GN
    Genes Chromosomes Cancer; 2014 May; 53(5):432-45. PubMed ID: 24493355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions.
    Cisco RM; Norton JA
    Future Oncol; 2008 Aug; 4(4):553-9. PubMed ID: 18684065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hereditary diffuse gastric cancer].
    Puchmajerová A; Vasovčák P; Macháčková E; Foretová L; Křepelová A
    Klin Onkol; 2012; 25 Suppl():S30-3. PubMed ID: 22920204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease.
    Gullo I; Devezas V; Baptista M; Garrido L; Castedo S; Morais R; Wen X; Rios E; Pinheiro J; Pinto-Ribeiro I; Ferreira RM; Preto J; Santos-Antunes J; Marques M; Campos M; Almeida F; Espinheira MDC; Amil Dias J; Figueiredo C; Oliveira C; Trindade E; Carneiro F
    Gastrointest Endosc; 2018 Jun; 87(6):1566-1575. PubMed ID: 29454568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A RAND/UCLA appropriateness study of the management of familial gastric cancer.
    Dixon M; Seevaratnam R; Wirtzfeld D; McLeod R; Helyer L; Law C; Swallow C; Paszat L; Bocicariu A; Cardoso R; Mahar A; Bekaii-Saab T; Chau I; Church N; Coit D; Crane CH; Earle C; Mansfield P; Marcon N; Miner T; Noh SH; Porter G; Posner MC; Prachand V; Sano T; Van de Velde CJ; Wong S; Coburn N
    Ann Surg Oncol; 2013 Feb; 20(2):533-41. PubMed ID: 22941158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic testing by cancer site: stomach.
    Chun N; Ford JM
    Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cate's Story: Hereditary Diffuse Gastric Cancer.
    Rogers M
    Clin J Oncol Nurs; 2016 Aug; 20(4):443-5. PubMed ID: 27441520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer.
    Oliveira C; Pinheiro H; Figueiredo J; Seruca R; Carneiro F
    Prog Mol Biol Transl Sci; 2013; 116():337-59. PubMed ID: 23481202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer.
    Guilford PJ; Hopkins JB; Grady WM; Markowitz SD; Willis J; Lynch H; Rajput A; Wiesner GL; Lindor NM; Burgart LJ; Toro TT; Lee D; Limacher JM; Shaw DW; Findlay MP; Reeve AE
    Hum Mutat; 1999; 14(3):249-55. PubMed ID: 10477433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
    Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Germline E-cadherin gene mutation screening in familial gastric cancer kindreds].
    Jiang Y; Wan YL; Wang ZJ; Zhao B; Zhu J; Huang YT
    Zhonghua Wai Ke Za Zhi; 2004 Aug; 42(15):914-7. PubMed ID: 15363252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene.
    More H; Humar B; Weber W; Ward R; Christian A; Lintott C; Graziano F; Ruzzo AM; Acosta E; Boman B; Harlan M; Ferreira P; Seruca R; Suriano G; Guilford P
    Hum Mutat; 2007 Feb; 28(2):203. PubMed ID: 17221870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lobular breast cancer in a CDH1 splice site mutation carrier: case report and review of the literature.
    McVeigh TP; Choi JK; Miller NM; Green AJ; Kerin MJ
    Clin Breast Cancer; 2014 Apr; 14(2):e47-51. PubMed ID: 24333020
    [No Abstract]   [Full Text] [Related]  

  • 37. CDH1/E-cadherin germline mutations in early-onset gastric cancer.
    Bacani JT; Soares M; Zwingerman R; di Nicola N; Senz J; Riddell R; Huntsman DG; Gallinger S
    J Med Genet; 2006 Nov; 43(11):867-72. PubMed ID: 16801346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genetic background and clinical features of hereditary diffuse gastric cancer].
    Vasas P; Bijendra P
    Orv Hetil; 2011 Jul; 152(28):1105-9. PubMed ID: 21737393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk.
    Lei H; Sjöberg-Margolin S; Salahshor S; Werelius B; Jandáková E; Hemminki K; Lindblom A; Vorechovský I
    Int J Cancer; 2002 Mar; 98(2):199-204. PubMed ID: 11857408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
    Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.